• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » New Combination Treatment Mitigates Antipsychotic-Induced Weight Gain

New Combination Treatment Mitigates Antipsychotic-Induced Weight Gain

July 14, 2021
Susie Morris, MD.
From The Carlat Hospital Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Susie Morris, MD. Dr. Morris has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Correll CU et al, Am J Psychiatry 2020;177(12):1168–1178

To date, we have had no FDA-approved medications to mitigate antipsychotic-­associated weight gain (AIWG). This will soon change, thanks to recent research showing that samidorphan, an opioid receptor antagonist, appears to significantly lessen weight gain associated with the use of olanzapine (Editor’s note: The FDA approved the olanzapine/samidorphan combination on June 1, 2021).

In this 24-week, double-blind trial, 352 adults with schizophrenia were randomized to receive either olanzapine alone (n = 176) or a combination tablet of olanzapine and samidorphan (n = 176). Olanzapine doses were 10 or 20 mg daily, and the samidorphan dose was 10 mg daily. Alkermes, the manufacturer of the combination drug, sponsored the study. Exclusion criteria were strict and included treatment-resistant schizophrenia, substance use disorders, any clinically significant medical illness (eg, diabetes or hypertension), obesity (BMI > 30), and recent use of opioids or opioid antagonists.

At the 24-week endpoint of the study, patients on olanzapine/samidorphan gained 4.2% of their body weight, significantly less than the 6.6% gained by those taking olanzapine alone. Other key outcomes favoring olanzapine/samidorphan included the proportion of subjects who gained more than 10% of their baseline body weight (18% in the combined treatment group vs 30% in the olanzapine-only group) and the mean change in baseline waist circumference (2.4 cm in the combined treatment group vs 4.5 cm in the olanzapine-only group). Metabolic changes were minimal for both groups. Dropout rates were primarily associated with adverse events, impacting 12% of the combined treatment group and 9.8% of the olanzapine-only group.

The most common adverse events were weight gain and increased appetite (more in the olanzapine-only group), and somnolence and dry mouth (more in the combined treatment group). The addition of samidorphan did not affect antipsychotic efficacy. About one-third of patients dropped out due to side effects, loss to follow-up, or unspecified reasons.

CHPR’s Take
Adding samidorphan to olanzapine appears to decrease weight gain, but the effect in the study was only moderate. To put these results in perspective, a patient starting the trial at 150 pounds would have gained an average of 9.9 pounds on olanzapine vs 6.3 pounds on the combination. In addition, the exclusion criteria prevented many real-world patients from entering the trial. Especially in the inpatient world, it is unusual to find patients with schizophrenia who do not have either a substance use problem or a significant medical problem, so we don’t know if this study’s findings apply to our typical patients. Still, given how problematic AIWG can be for our patients, this new treatment may become a useful tool.
Hospital Psychiatry
KEYWORDS metabolic-syndrome olanzapine opioid-antagonist samidorphan schizophrenia weight-gain
    Susie Morris, MD.

    Antipsychotics in Inpatient Children and Adolescents with Seclusion and Restraint

    More from this author
    www.thecarlatreport.com
    Issue Date: July 14, 2021
    SUBSCRIBE NOW
    Table Of Contents
    CME Post-Test - Metabolic Side Effects, CHPR, July/August/September 2021
    Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain
    Weight Gain and Metabolic Side Effects
    Sex-Based Treatment of Schizophrenia
    New Combination Treatment Mitigates Antipsychotic-Induced Weight Gain
    Anti-NMDA Receptor Encephalitis or New-Onset Psychosis?
    Psilocybin: The New Holy Grai­l for the Rapid Relief of Major ­Depression?
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.